Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

Authors:

Abstract
No abstract available
Funding Information
  • Novartis Pharma
  • Novartis Pharmaceuticals Corporation
  • Research Council of Norway (273563)

This publication has 48 references indexed in Scilit: